Articles tagged "Co-stimulation"

2020 American Transplant Congress
Is it Time for Immune Screening for Belatacept-Treated Stable Kidney Transplant Patients for Adjust the Immunosuppression?
M. C. Rial¹, F. Caro², N. Ambrosi², D. Guerrieri², A. Calleri¹, E. Chuluyan¹, D. Casadei¹
¹ITAC, Buenos Aires, Argentina, ²CEFYBO, UBA, Buenos Aires, Argentina
*Purpose: Belatacept is a co-stimulation blocker for primary maintenance immunosuppression in kidney transplant recipients. The goal of this work was to study the immunological status…
2020 American Transplant Congress
A Novel Injectable Hydrogel-Based Approach to Localize and Tune the Actuation of Enhanced Costimulation Blockade to the Strength of Transplant Rejection
A. Komin¹, C. Liang², P. Majumder², X. Calderon-Colon³, O. Tiburzi³, M. Iglesias Lozano¹, Y. Zhang¹, G. Brandacher¹, J. Patrone³, J. Schneider², G. Raimondi¹
¹Johns Hopkins School of Medicine, Baltimore, MD, ²NIH National Cancer Institute, Frederick, MD, ³JHU Applied Physics Laboratory, Laurel, MD
*Purpose: Complications from long-term use of calcineurin inhibitors remain a major issue for transplant patients and alternative therapies are needed. The clinical efficacy of CTLA4-Ig…
2020 American Transplant Congress
Analysis of Rejection, Rejection Therapy and Renal Function in the BEST Trial
H. Kuzaro¹, A. R. Shields², A. Wiseman³, S. Tremblay¹, A. Christianson¹, D. Kaufman⁴, J. Leone⁵, A. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Colorado, Denver, CO, ⁴U Wisconsin, Madison, WI, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷UIC, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal) compared two belatacept (BELA)-based early corticosteroid withdrawal (ESW) regimens and alemtuzumab (ALEM) or rabbit antithymocyte globulin (rATG)…
2020 American Transplant Congress
Effector Differentiation of Endogenous Antigen-Specific CD8⁺ T Cells is Selectively Limited by CTLA-4 Ig
S. M. Krummey, K. P. Tong, M. L. Ford
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Costimulation blockade with belatacept (CTLA-4 Ig) offers improved renal function and reduced toxicity following transplantation compared to calcineurin inhibitors. Nonetheless, episodes of acute T…
2020 American Transplant Congress
Two Pilot Studies Exploring the Diagnostic and Predictive Potential of Serum LAG3 and FGL1 in Kidney Transplant Recipients
Y. Li¹, L. Yan¹, Y. Li¹, C. Yang¹, Z. Wan¹, Y. An¹, Y. Bai¹, L. Wang¹, Y. Shi²
¹Department of Laboratory Medicine, West China Hospital, Chengdu, China, ²Department of Nephrology, West China Hospital, Chengdu, China
*Purpose: Lymphocyte activation gene 3 (LAG3), an immune checkpoint, plays an important role in the negative regulation of immune response and the induction of immune…
2020 American Transplant Congress
Belatacept Provides Superior Inhibition of Donor Specific Antibody Formation in Kidney Transplant Recipients with Acute Rejection
O. Cristea, C. Larsen, I. Badell
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: The factors responsible for chronic renal allograft dysfunction and premature graft loss are incompletely understood and likely multifactorial. Immunologic injury partially attributable to the…
2020 American Transplant Congress
Belatacept Combined with BTLA Prolong Allogeneic Kidney Graft Survival and Inhibited Acute Rejection after Kidney Transplantation
H. Zhang, Z. Wang, J. Zhang, Z. Han, J. Tao, H. Chen, L. Sun, R. Tan, M. Gu
Jiangsu Province Hospital, Nanjing, China
*Purpose: Belatacept as a high-affinity variant of CTLA-4Ig, has been applied into kidney transplantation to against acute rejection. However, adoption of Belatacept has been limited…
2020 American Transplant Congress
Naïve B Cells Regulation by TLR-Breg Cells In Vitro
Q. Fu, K. Lee, G. Huai, K. Deng, N. J. Feeney, C. Leguern, S. Deng, J. F. Markmann
Center for Transplant Science, MGH, Boston, MA
*Purpose: Regulatory B cells (Bregs) have shown great potential in cell therapies for murine organ transplantation by inhibiting the proliferation of cytotoxic and helper T…
2019 American Transplant Congress
Interruption of Notch Signaling via Blockade of Delta-Like Ligands 1 and 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection
A. Matar, Y. Dong, B. Lovasik, D. Mathews, A. Ghosh, C. Breeden, A. Stephenson, W. Kitchens, A. Adams
Surgery and Transplantation, Emory University, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…